comparemela.com

Latest Breaking News On - Augmentation of nuclear gene output is stoke - Page 1 : comparemela.com

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

– STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing.

United statesUnited kingdomEdwardm kayeInternational epilepsy congressCompany annual report on formAugmentation of nuclear gene output is stokeExchange commissionAmerican epilepsy societyStoke therapeutics incAcadia pharmaceuticalsAugmentation of nuclear gene outputStoke therapeuticsChief executive officerDominant optic atrophyYear to date financialCollaboration agreement

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

07.11.2023 - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of .

United kingdomUnited statesAugmentation of nuclear gene output is stokeAcadia pharmaceuticalsAmerican epilepsy societyAugmentation of nuclear gene outputStoke therapeutics incExchange commissionCompany annual report on formInternational epilepsy congressThird quarterDominant optic atrophyYear to date financialCollaboration agreementAutosomal dominant optic atrophyTargeted augmentation

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

DUBLIN (BUSINESS WIRE) Sep 5, 2023

United kingdomUnited statesHelen crossIm scott perryElaine wirrellEric rojasCompany annual report on formCook children medical centerExchange commissionStoke therapeutics incNeurology residency training program at mayo clinicJohn justin neurosciences centerInternational league against epilepsyInternational epilepsy congressUniversity college london institute of child healthAugmentation of nuclear gene output

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Trea

– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome –– Data support the potential for STK-001 to be the first disease-modifying treatment for Dravet syndrome –– New pharmac.

United kingdomUnited statesHelen crossEric rojasElaine wirrellIm scott perryExchange commissionInternational league against epilepsyAugmentation of nuclear gene output is stokeJohn justin neurosciences centerCook children medical centerStoke therapeutics incCompany annual report on formInternational epilepsy congressUniversity college london institute of child healthNeurology residency training program at mayo clinic

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

– STK-001: Additional data from patients treated with single and multiple doses along with data from open-label extension studies anticipated in Q1 2024 – – STK-001: Company plans to share.

United kingdomUnited statesEdwardm kayeStoke therapeutics incAcadia pharmaceuticalsAmerican epilepsy societyExchange commissionAugmentation of nuclear gene outputAugmentation of nuclear gene output is stokeInternational epilepsy congressCompany annual report on formRegulatory agencyStoke therapeuticsChief executive officerDominant optic atrophyClinical trial application

vimarsana © 2020. All Rights Reserved.